Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Apremilast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,865Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Macleods`s Generics Apremilast Receives Approval in US
    Macleods`s Generics Apremilast Receives Approval in US

    25 Nov 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211788

    FDA
    25 Nov 2024
    Share Share
    OTEZLA Now Available In US For Pediatric Plaque Psoriasis
    OTEZLA Now Available In US For Pediatric Plaque Psoriasis

    20 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/otezla-apremilast-now-available-in-the-us-for-moderate-to-severe-pediatric-plaque-psoriasis-302225697.html

    PR NEWSWIRE
    20 Aug 2024
    Share Share
    AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND
    AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND

    02 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amgen-announces-2024-third-quarter-dividend-302213618.html

    PR NEWSWIRE
    02 Aug 2024
    Share Share
    Amgen 1Q Results
    Amgen 1Q Results

    21 May 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-05-21/amgen-1q-results/?widget=listSection

    CONTRACT PHARMA
    21 May 2024
    Share Share
    Amgen Presents New Research On Otezla® (Apremilast) At Aad 2024
    Amgen Presents New Research On Otezla® (Apremilast) At Aad 2024

    09 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amgen-presents-new-research-on-otezla-apremilast-at-aad-2024-302084594.html

    PR NEWSWIRE
    09 Mar 2024
    Share Share
    Mankind Pharma`s Generic Apremilast Receives Approval in the U.S.
    Mankind Pharma`s Generic Apremilast Receives Approval in the U.S.

    07 Feb 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211734

    FDA
    07 Feb 2024
    Share Share